#3 - Amgen (NASDAQ:AMGN)
Amgen Inc. (NASDAQ: AMGN) is a good reminder that even “forever stocks” can have a bad year. AMGN stock is one of the worst-performing Dow 30 stocks in 2024. It’s down about 7.3% for the year as of December 18.
However, the company is at the forefront of cancer treatment, as evidenced by two significant announcements in December 2024. First, the company shared positive clinical trial results showing that adding its drug BLINCYTO to chemotherapy improved disease-free survival rates in newly diagnosed pediatric leukemia patients. Second, Amgen announced a $1 billion expansion to its manufacturing facility in North Carolina.
That should give investors good reason to zoom out and look at the stock’s 20-year total return of 500.76%. This includes a dividend with a 3.64% yield and an impressive annual payout of $9.52 per share.
MarketBeat shows 26 analysts covering Amgen—12 give the stock a Buy rating, with two of those being Strong Buy ratings.
About Amgen
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
More- Current Price
- $293.54
- Consensus Rating
- Hold
- Ratings Breakdown
- 12 Buy Ratings, 10 Hold Ratings, 2 Sell Ratings.
- Consensus Price Target
- $313.23 (6.7% Upside)
